This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Study design
The study was a randomised-controlled trial, carried out in a single centre. The duration of the follow-up appears to have been up to the morning of the third postoperative day. Loss to follow-up was not reported. The patients were assigned to the ALB or the HES group using random numbers. During the peri-operative observation period, measurements were made pre-operatively, at the end of surgery and on the morning of the first and third postoperative days.
Analysis of effectiveness
The principle (intention to treat or treatment completers only) used in the analysis of effectiveness was not explicitly specified. The clinical outcome measures were colloid administration on the day of surgery; haemodynamic, coagulation and renal function parameters; total serum protein and the colloid osmotic pressure; blood loss and requirement for blood components. The study groups were comparable in terms of demographic data, pre-existing diseases and ASA risk classification.
Effectiveness results
Colloid administration on the day of surgery was 38.4 ml/kg in the HES group and 35.1 ml/kg in the ALB group. Haemodynamic, coagulation and renal function parameters were similar. Although total serum protein was still different on the third postoperative day (53.45 g/l in the HES group and 60.6 g/l in the ALB group, p< 0.01) the colloid osmotic pressure always remained above 19.5 (2.5) mmHg in the HES group. Blood loss (3,810 (1,632) ml in the HES group and 3,455 (1,733) ml in the ALB group) and the requirement for blood components were comparable.
Clinical conclusions
In this study, the authors found that the haemodynamic effect of HES was comparable to that of 5% albumin throughout the whole period, and that haemodynamic-related variables remained within physiological limits.
Measure of benefits used in the economic analysis
No summary benefit measure was identified in the economic analysis, and only separate clinical outcomes were reported.
